https://scholars.lib.ntu.edu.tw/handle/123456789/596497
標題: | Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey) | 作者: | Chuah Y.-Y. Wu D.-C. Chuah S.-K. JYH-CHIN YANG Lee T.-H. Yeh H.-Z. Chen C.-L. Liu Y.-H. Hsu P.-I. |
關鍵字: | expectation; Helicobacter pylori eradication; real-world practice | 公開日期: | 2017 | 出版社: | Blackwell Publishing Ltd | 卷: | 22 | 期: | 3 | 來源出版物: | Helicobacter | 摘要: | Objective: The aims of the study were: 1, to survey the most popular anti-H.?pylori regimens in Asia-Pacific region and the real-world effectiveness of these regimens; and 2, to investigate the expectation gaps of eradication rate between physicians and patients. Design: A questionnaire was distributed to Asia-Pacific physicians who attended the Asia-Pacific Digestive Week 2015 meeting. Reported eradication rates from the literatures were compared with real-world rates of surveyed popular regimens within the region. In addition, a questionnaire was distributed to H.?pylori-infected patients in three regions of Taiwan. Results: A total of 691 physicians and 539 patients participated in the survey. The top five most commonly used regimens were 7-day clarithromycin-based standard triple therapy (50.4%), 14-day clarithromycin-based standard triple therapy (31.0%), 10-day sequential therapy (6.1%), 14-day bismuth quadruple therapy (3.9%), and 14-day hybrid therapy (3.6%). All countries except for China had a significant gap between the expectation of physicians on anti-H.?pylori therapy and the real-world eradication rate of most commonly adopted regimens (all P value <.05). The expectation on minimal eradication rate among patients was higher than that of physicians (91.4% vs 86.5%, P<.001). Conclusions: It is time for physicians in Asia-Pacific countries to adopt newer and more efficacious anti-H.?pylori regimens to meet the Kyoto consensus recommendation and their patients’ expectations. ? 2017 John Wiley & Sons Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014146914&doi=10.1111%2fhel.12380&partnerID=40&md5=158d5e0233be786018c57da1666d02b9 https://scholars.lib.ntu.edu.tw/handle/123456789/596497 |
ISSN: | 1083-4389 | DOI: | 10.1111/hel.12380 | SDG/關鍵字: | bismuth; clarithromycin; antiinfective agent; Article; China; clinical effectiveness; clinical practice; cost benefit analysis; doctor patient relation; drug effect; eradication therapy; expectation; health insurance; Helicobacter infection; human; major clinical study; Taiwan; treatment duration; treatment planning; Asia; clinical practice; cross-sectional study; drug therapy; female; Helicobacter infection; male; Pacific islands; procedures; questionnaire; treatment outcome; Anti-Bacterial Agents; Asia; Cross-Sectional Studies; Drug Therapy; Female; Helicobacter Infections; Humans; Male; Pacific Islands; Practice Patterns, Physicians'; Surveys and Questionnaires; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。